Feb. 21, 2025
| Today’s news and insights for biopharma leaders
The pioneering gene therapy developer will be acquired by investment firms Carlyle Group and SK Capital for a fraction of what it was once worth.
|
Originally scheduled for next week, the meeting of agency advisers will be delayed to give more time for public comment, an HHS spokesperson said.
|
News roundup
The FDA determined that Novo Nordisk’s obesity and diabetes drugs are no longer in short supply. Elsewhere, Concentra made a competing bid for Acelyrin and Intra-Cellular sales rose.
|
The latest checklist from AiCure showcases essential features to look for when choosing a platform for your study.
|
Layoffs at the FDA’s device center could add “months, if not years” to the time it takes to bring products to market, one attorney said.
|
Pfizer’s decision to halt further marketing of Beqvez is further sign of the sparse patient interest in gene therapies for the bleeding condition.
|
|
Advanced Practice Providers are integral to patient care. Learn how APPs influence treatment plans and how brands can connect with them to enhance patient journeys and improve results in this playbook.
|
|
From Our Library
Trendline
Supported by Premier Inc
|
Playbook
Custom content for Integrity Solutions
|
Webinar - on demand
Custom content for Tive
|
Playbook
Custom content for AgriNovus
| | 
